All In Biotech

Drug Trial Radar · NCT00811941

Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence

Last checked: Nov 20, 2026Latest source record: Aug 7, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 665 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

665

Actual

Start

Mar 2009

Primary completion

Nov 2010

Study completion Nov 2010

Sponsor

Lead sponsor
H. Lundbeck A/SIndustry
Sponsor type
Industry
First posted
Dec 19, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is long-term safety, tolerability and efficacy of nalmefene in patients with alcohol dependence.

Conditions

  • Alcohol Dependence

Interventions

  • PlaceboDrug

    as-needed use, tablets, orally, 52 weeks

  • NalmefeneDrug

    18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With Adverse Events (AEs)Time frame: Serious Adverse Events: 52 weeks and a safety follow-up (visit/telephone call) scheduled for 4 weeks after completion of the study or after withdrawal from the study. Other Adverse Events: 52 weeks.
  2. Percentage of Patients Who Withdrew Due to Intolerance to TreatmentTime frame: Baseline to Week 52
  3. Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)Time frame: Baseline and Month 6
  4. Change From Baseline in the Monthly Total Alcohol Consumption (TAC)Time frame: Baseline and Month 6

Locations

60 sites in 10 countries. Site status is shown where the registry gives one.

  • CZ007

    Litoměřice, Czechia

  • CZ006

    Lnáře, Czechia

  • CZ005

    Prague, Czechia

  • CZ004

    Prague, Czechia

  • CZ001

    Ústí nad Labem, Czechia

  • EE002

    Pärnu, Estonia

  • EE004

    Tallinn, Estonia

  • EE005

    Tallinn, Estonia

  • EE001

    Võru, Estonia

  • EE003

    Vorumaa, Estonia

  • HU004

    Budapest, Hungary

  • HU002

    Budapest, Hungary

  • LV003

    Daugavpils, Latvia

  • LV002

    Jelgava, Latvia

  • LV001

    Riga, Latvia

  • LV004

    Sigulda, Latvia

  • LT002

    Kaunas, Lithuania

  • LT003

    Kaunas, Lithuania

  • PL015

    Bełchatów, Poland

  • PL008

    Bydgoszcz, Poland

  • PL006

    Gdansk, Poland

  • PL011

    Krakow, Poland

  • PL002

    Leszno, Poland

  • PL010

    Lodz, Poland

  • PL014

    Lodz, Poland

  • PL004

    Lublin, Poland

  • PL005

    Lublin, Poland

  • PL013

    Piekary Śląskie, Poland

  • PL003

    Skorzewo, Poland

  • PL007

    Starogard Gdański, Poland

  • PL012

    Swicie n/Wisla, Poland

  • PL009

    Szczecin, Poland

  • PL001

    Torun, Poland

  • RU013

    Rostov-on-Don, Russia

  • RU002

    Saint Petersburg, Russia

  • RU005

    Saint Petersburg, Russia

  • RU006

    Saint Petersburg, Russia

  • RU001

    Saint Petersburg, Russia

  • RU012

    Saint Petersburg, Russia

  • RU003

    Saint Petersburg, Russia

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.